Achilles Therapeutics (ACHL) shares were up 1.1% Tuesday morning after the company said it sold certain technology assets to AstraZeneca (AZN) for $12 million.
The company said it transferred a commercial license of proprietary data and samples from the TRACERx non-small cell lung cancer study to AstraZeneca.
Achilles said the sale concludes a strategic review it had first announced in September. The company said it now plans to further reduce its employee headcount and decrease the size of its board.
Price: 0.99, Change: +0.01, Percent Change: +1.11
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。